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Open access under CC BY-NC-ND license.BACKGROUND & AIMS: We performed an open-label, multi-
center, phase 3 study of the safety and efﬁcacy of twice-daily
telaprevir in treatment-naive patients with chronic hepatitis C
virus (HCV) genotype 1 infection, including those with
cirrhosis. METHODS: Patients were randomly assigned to
groups treated with telaprevir 1125 mg twice daily or 750 mg
every 8 hours plus peginterferon alfa-2a and ribavirin for 12
weeks; patients were then treated with peginterferon alfa-2a
and ribavirin alone for 12 weeks if their level of HCV RNA at
week 4 was <25 IU/mL or for 36 weeks if their level was
higher. The primary objective was to demonstrate non-
inferiority of telaprevir twice daily versus every 8 hours in
producing a sustained virological response 12 weeks after the
end of therapy (SVR12) (based on a –11% lower limit of the
95% lower conﬁdence interval for the difference between
groups). RESULTS: At baseline, of 740 patients, 85% had
levels of HCV RNA 800,000 IU/mL, 28% had ﬁbrosis
(F3–F4), 14% had cirrhosis (F4), 57% were infected with HCV
genotype 1a, and 71% had the non-CC IL28B genotype. Of pa-
tients who were treated with telaprevir twice daily, 74.3%
achieved SVR12 compared with 72.8% of patients who were
treated with telaprevir every 8 hours (difference in response,
1.5%; 95% conﬁdence interval, –4.9% to 12.0%), so telaprevir
twice daily is noninferior to telaprevir every 8 hours. All sub-
groups of patients whowere treatedwith telaprevir twice daily
versus those who were treated every 8 hours had similar rates
of SVR12. The most frequent adverse events (AEs) in the
telaprevir phase were fatigue (47%), pruritus (43%), anemia
(42%), nausea (37%), rash (35%), and headache (26%);
serious AEs were reported in 9% of patients. Rates of AEs and
serious AEs were similar or slightly higher among patients
treated with telaprevir every 8 hours. CONCLUSIONS: Based
on a phase 3 trial, telaprevir twice daily is noninferior to
every 8 hours in producing SVR12, with similar levels of
safety and tolerability. These results support use of telaprevir
twice daily in patients with chronic HCV genotype 1 infection,
including those with cirrhosis. ClinicalTrials.gov, Number:
NCT01241760.Keywords: OPTIMIZE; Clinical Trial; Protease Inhibitor; DAA.
he NS3/4A protease inhibitor telaprevir (TVR), inTcombination with peginterferon (PEG-IFN) alfa-2a
and ribavirin (RBV), is approved at a dose of 750 mg
every 8 hours for the treatment of genotype 1 (G1) chronic
hepatitis C virus (HCV) infection in adults with compensated
liver disease who are treatment naive or have previously
received interferon-based treatment.1,2 Reducing the fre-
quency of TVR dosing to twice daily to coincide with RBV
dosing and to allow for easier coordination with mealtimes
(to optimize absorption) may be beneﬁcial for patient
adherence and treatment success.
Twice-daily dosing of TVR was previously explored in the
phase 2 C208 clinical study (NCT00528528), which evaluated
the efﬁcacy, safety, and pharmacokinetics (PK) of 12 weeks of
treatment with TVR 1125 mg every 12 hours or TVR 750 mg
every 8 hours in combination with a maximum of 48 weeks of
treatment with PEG-IFN alfa-2a/RBV or PEG-IFN alfa-2b/RBV
in 161 treatment-naive, predominantly noncirrhotic patients.3
In this study, sustained virological response (SVR) rates were
similar between groups, with>80% of patients achieving SVR
regardless of the dosing frequency of TVR. Viral breakthrough
and relapse were infrequent in all treatment groups, with no
statistically signiﬁcant differences observedbetweendosing of
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RTVRevery8hoursor every12hours. ThePKanalysis showeda
higher maximum concentration (Cmax) and lower predose
concentration when TVR was given every 12 hours compared
with every 8 hours, but this difference did not translate into
any differences in clinical outcome. In addition, the safety
proﬁle was similar in both treatment groups. However, given
the small number of patients per arm, conﬁrmation of these
results was warranted in a larger clinical trial.
OPTIMIZE is the ﬁrst phase 3 trial to investigate the use
of TVR twice daily versus every 8 hours in combination with
PEG-IFN/RBV. Here we present ﬁndings on the efﬁcacy and
safety of the 2 dosing regimens in treatment-naive patients
with G1 HCV, including patients with cirrhosis.
Patients and Methods
Patients
Patients were enrolled at 125 international sites. The study
was initiated on November 15, 2010, and completed on
November 28, 2012. Eligible patients were 18 to 70 years of
age and treatment naive, with HCV RNA levels >1000 IU/mL
and evidence of chronic HCV infection conﬁrmed by detectable
HCV RNA >6 months before the screening visit or by histo-
logical diagnosis based on liver biopsy. All patients had a
documented liver biopsy <2 years before screening or had a
biopsy performed within the screening period. Patients were
excluded if they had an HCV genotype other than 1 or if they
had received prior HCV treatment. Patients were not eligible if
they had decompensated liver disease, hepatocellular carci-
noma, or signiﬁcant liver disease in addition to hepatitis C,
including drug- or alcohol-related cirrhosis.
Study Design
OPTIMIZE was a randomized, open-label, multicenter, phase
3 study comparing the efﬁcacy, safety, and tolerability of TVR
1125 mg twice daily versus TVR 750 mg every 8 hours, each in
combination with PEG-IFN/RBV (NCT01241760). The study
consisted of a screening period of approximately 4 weeks, a
treatment phase of 24 or 48 weeks, and a follow-up period of at
least 24 weeks. Written informed consent was obtained from all
study participants. The study protocol was reviewed and
approvedby the appropriate reviewboards or institutional ethics
committees and health authorities. The study was conducted in
accordance with the Declaration of Helsinki, the Good Clinical
Practice guidelines, and applicable regulatory requirements.
The primary study objective was to establish noninferiority
in SVR12 (deﬁned as plasma HCV RNA levels <25 IU/mL
12 weeks after the last planned dose of study drug) with dosing
of TVR twice daily compared with every 8 hours. The secondary
objectives of the study were to evaluate the effect of IL28B
genotype and liver ﬁbrosis stage on viral response and to
evaluate the tolerability and safety of TVR when administered
twice daily or every 8 hours. Other secondary objectives
included evaluating the PK of TVR, PEG-IFN, and RBV and to
investigate PK-pharmacodynamic relationships for safety and
efﬁcacy. Changes from baseline in the amino acid sequence of
the HCV NS3/4A region were also assessed.
Patients were randomized (1:1) to receive TVR twice daily or
every 8 hours and were stratiﬁed according to liver ﬁbrosis
stage and IL28B rs12979860 genotype CC, CT, or TT.4–6Randomization was performed using a central, computer-
generated schedule prepared under supervision of the sponsor
before the study. An interactive telephone or Internet system
assigned a unique code that dictated the treatment assignment
and matching study drug kit for the patient. Fibrosis stage was
assessed by liver biopsy and graded locally as no/mild ﬁbrosis
and portal ﬁbrosis (METAVIR F0–F2; Ishak score3) or bridging
ﬁbrosis and cirrhosis (METAVIR F3–F4; Ishak score 4).7
All patients received 12 weeks of treatment with TVR twice
daily or every 8 hours, each in combination with PEG-IFN/RBV.
TVR was administered orally at a dose of either 750 mg every
8 hours or 1125 mg twice daily (with a time window of 10–14
hours between twice-daily drug intake). The dosage of PEG-IFN
was 180 mg/wk, and the dosage of RBV was 1000 mg/day in pa-
tients weighing <75 kg or 1200 mg/day in patients weighing
75 kg. Patients assigned to the TVR twice daily group took RBV
with their dose of TVR. Patients assigned to TVR every 8 hours
could take RBV with 2 of the 3 daily doses of TVR, with the ﬁrst
dose always tobe takenwith themorning doseofTVR.Atweek12,
TVR dosing ended and patients continued on standard PEG-IFN/
RBV treatment. If a patient achieved a rapid virological response
(RVR; HCV RNA <25 IU/mL, target not detected at week 4 of
treatment), the total treatment durationwas 24weeks; otherwise,
the total treatment duration was 48 weeks. An electronic diary
(e-diary), completed by the patients, captured the amount and
timing of TVR dosing relative to the prescribed regimen.
Futility rules were applied to all patients to minimize the
risk of viral resistance in patients without an adequate antiviral
response. HCV RNA results were monitored, and all treatment
was stopped if HCV RNA levels were >1000 IU/mL at week 4
or 25 IU/mL at weeks 12, 24, 32, or 40.
TVR was permanently discontinued for any grade 4 adverse
event (AE) or toxicity that was considered at least possibly
related to TVR or for any patient experiencing a severe skin
reaction. TVR was not restarted once discontinued due to an AE
or toxicity considered at least possibly related to TVR. RBV
dosing, including modiﬁcations to manage anemia, followed
local prescribing instructions. If RBV was permanently dis-
continued for the management of anemia, TVR was also
permanently discontinued. RBV could be restarted as per the
dosing modiﬁcation guidelines.8
Study Evaluations and Statistical Methods
Efﬁcacy assessments and end points. Blood
samples for quantiﬁcation of HCV RNA were obtained during
screening; at day 1 predose (baseline); at weeks 4, 8, 12, 24, 32,
40, and 48 or time of discontinuation; and during follow-up.
Plasma HCV RNA values were quantiﬁed using the COBAS
TaqMan HCV test (version 2.0; lower limit of quantiﬁcation, 25
IU/mL) using the high pure system method of extraction.
Values below the lower limit of quantiﬁcation were reported as
<25 IU/mL detectable if a signal was detected or <25 IU/mL
target not detected if no target was detected.
The intent-to-treat population (ITT) included all randomized
patients who received at least one dose of TVR, irrespective of
protocol compliance. The ITT population was the primary popu-
lation for the efﬁcacy analyses, including the evaluation of non-
inferiority. On-treatment virological failure was deﬁned as
patients who met a virological stopping rule or experienced viral
breakthrough (>1-log increase in HCV RNA level from the nadir
value or HCV RNA level>100 IU/mL in patients whose HCV RNA
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LIVERlevel had previously become <25 IU/mL during treatment).
Analysis of the primary end point was performed when patients
had either completed the follow-up visit 12 weeks after the last
planned dose of study drug or had discontinued earlier
(SVR12planned) and was conducted using a snapshot approach
(SVR assessment based on the last HCVRNA value) in theweek 12
follow-up visit window. Relapse was deﬁned as all non-SVR12
patients who had an HCV RNA level <25 IU/mL at the end of
treatment but whose HCV RNA levels were 25 IU/mL during
follow-up. In addition to the ITT population, supportive efﬁcacy
analyses were also performed on the per-protocol population,
whichwas all randomized patientswho received at least one dose
of study medication without any major protocol deviation that
could signiﬁcantly affect efﬁcacy. Major protocol deviations
included patients not meeting the selection criteria, wrong treat-
ment or incorrect dose, and patients receiving disallowed
concomitant medication.
Noninferiority assessment was conducted using a logistic
regressionmodel including IL28B genotype, baseline liver ﬁbrosis
stage, and their interaction and baseline HCV RNA level as cova-
riates. Noninferiority was conﬁrmed if the lower limit of the 95%
conﬁdence interval (CI) of the difference between TVR twice daily
and every 8 hours was greater than –11%. The noninferiority
margin was prespeciﬁed using available meta-analysis data
and was determined based on both statistical and clinical con-
siderations and followed standard methodology endorsed by
regulatory agencies. The pooled SVR rate with TVR every 8
hours/PEG-IFN and RBV in 3 previous phase 2 and 3 randomized,
placebo-controlled studies9–11 was 72% and the overall effect
size versus placebo was 28%, with a lower 95% CI of 23%. To be
conservative, the lower CI was used and the margin was further
reduced to account for potential loss of effect in this study. Only
half of the statistical margin was retained using conservative
clinical judgment, setting the clinical margin at 11.5%, and giving
a ﬁnal noninferiority margin of 11%. A sample size of 704 pa-
tients, including 352 patients in each treatment group, was
considered sufﬁcient for showing noninferiority of TVR twice-
daily dosing. Assuming an expected SVR12 rate of 72% in each
group and a noninferiority margin of –11%, this sample size
provided 90% power to reject the inferiority hypothesis.
Secondary efﬁcacy variables included the proportion of
patients who achieved RVR, achieved SVR at week 24, experi-
enced a relapse, and experienced on-treatment virological
failure. For virological responses, data were analyzed without
imputation (“observed” analyses) and using a noncompleter
equals failure (NC ¼ F) imputation. Intermittent missing values
were imputed as a “response” if the immediate preceding and
following visits showed a response and as “no response”
otherwise. If any study drug was prematurely discontinued due
to virological failure, “no response” was imputed. If any study
drug was prematurely discontinued for another reason (ie, not
related to virological failure), missing data were marked as
“missing for another reason.” However, missing HCV RNA as-
sessments at the SVR12 visit were not imputed and were
considered treatment failures (no SVR). Additional sensitivity
analyses were also performed to compare virological response
rates (Supplementary Methods).
Descriptive statistics of treatment adherence and the number
of patients in each adherence category were reported for TVR
dosing frequency, timing of intake, and intakebasedon the e-diary.
This diary captured the amount and timing of TVR dosing relativeto the prescribed regimen. Additionally, adherence to dosing of
TVR and PEG-IFN/RBV was measured by dispensed versus
returnedmedications (pill count). Adherencewasexpressedas the
percentage of prescribed doses during the treatment period and
categorized by deﬁned thresholds. The e-diary analysis was per-
formed using the ITT population, with missing entries considered
0% adherent. Observed data analyses were also performed.
The 95% CIs stated in the report were part of the pre-
speciﬁed statistical analysis and provided an informal com-
parison within the framework of noninferiority. P values stated
in the report for the secondary efﬁcacy variables and subgroup
analyses were from post hoc statistical testing.
Virological, safety, and PK assessments. HCV
NS3/4A population sequencing was performed on plasma samples
at baseline and in the case of virological failure or relapse. The
frequency of TVR-resistant variants is presented descriptively.
Individual empirical Bayesian estimates of TVR PK parame-
ters were determined using a population PKmodeling approach.
Blood samples (sparse sampling) were taken at sites with the
capabilities for PK sampling at weeks 2, 4, 6, and 8 to determine
concentrations of TVR, PEG-IFN, and RBV for adherence assess-
ments as well as for PK evaluations. An additional sample was
collected for analysis of TVR if a patient discontinued TVR due to
an AE and was to be taken as close as possible to the time of
discontinuation. PK-pharmacodynamic relationships for both
safety and efﬁcacy were evaluated. No formal PK analysis was
conducted for RBV and PEG-IFN, although descriptive statistics
were calculated for each time point.
An independent data and safety monitoring board was used
throughout the study. The ITT population was used for the
safety analysis. Safety data were summarized for the TVR
treatment phase (from the date of ﬁrst intake of study drug to
the date of last TVR intake plus 1 day) and for the overall
treatment phase (from the date of ﬁrst intake of study drug to
the date of last intake of study drug plus 30 days). Special
search categories (SSCs) were created by grouping AE terms
representing similar medical concepts from the same or
different body systems to ensure that each patient was counted
only once. The grade and severity of rash events were assigned
using criteria previously described.1,2,12
Anemia as an AE was graded by the investigator with guid-
ance on grading hemoglobin levels using the Division of AIDS
table for grading the severity of AEs. In addition, hemoglobin
levels were measured throughout the trial, such that both he-
moglobin levels and the AE of anemia were analyzed separately.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.
Results
Patient Disposition and Baseline
Characteristics
A total of 884 patients were screened. Of these, 740 pa-
tientswere randomized and treatedwith TVR twice daily (n¼
369) or every 8 hours (n ¼ 371) (Supplementary Figure 1).
Overall, 90% of patients completed the study. Reasons for
discontinuation were primarily loss to follow-up (5%) or
withdrawal of consent (4%) (Supplementary Figure 1).
The demographic and baseline disease characteristics
are shown in Table 1. The baseline characteristics were
Table 1.Baseline Demographics and Disease Characteristics
TVR twice daily (n ¼ 369) TVR every 8 hours (n ¼ 371) All patients (N ¼ 740)
Age (y), mean (SD) 48 (11) 48 (11) 48 (11)
Body mass index (kg/m2), mean (SD) 26 (5) 27 (5) 27 (5)
Male sex 209 (57) 235 (63) 444 (60)
Race
Asian 10 (3) 6 (2) 16 (2)
Black 20 (5) 15 (4) 35 (5)
Multiple 6 (2) 3 (0.8) 9 (1)
White 333 (90) 347 (94) 680 (92)
Region
Europe 179 (49) 192 (52) 371 (50)
North America 137 (37) 126 (34) 263 (36)
Baseline log10 HCV RNA (IU/mL),
a mean IU/mL (SD) 6.48 (0.7) 6.49 (0.7) 6.49 (0.7)
Baseline HCV RNAa
<800,000 IU/mL 57 (15) 54 (15) 111 (15)
800,000 IU/mL 312 (85) 317 (85) 629 (85)
HCV genotype subtypeb
1a 210 (57) 209 (56) 419 (57)
1b 157 (43) 160 (43) 317 (43)
IL28B subtypec
CC 105 (28) 106 (29) 211 (29)
CT 206 (56) 208 (56) 414 (56)
TT 58 (16) 57 (15) 115 (16)
Baseline ﬁbrosis stagec
No or minimal ﬁbrosis (F0/1) 172 (47) 177 (48) 349 (47)
Portal ﬁbrosis (F2) 95 (26) 85 (23) 180 (24)
Bridging ﬁbrosis (F3) 48 (13) 59 (16) 107 (15)
Cirrhosis (F4) 54 (15) 49 (13) 103 (14)
Otherd 0 1 (0.3) 1 (0.1)
NOTE. Values are expressed as n (%) unless otherwise noted.
SVR12, sustained virological response deﬁned as plasma HCV RNA levels <25 IU/mL at 12 weeks after the last planned dose
of study drug.
aHCV RNA levels were measured with the use of COBAS TaqMan HCV assay (version 2.0; Roche, Basel, Switzerland). Lower
limit of quantiﬁcation was 25 IU/mL.
bHCV genotype and subtype were determined using NS3 assay.
cStratiﬁcation factor. For ﬁbrosis stage, stratiﬁcation factors were F0–2 versus F3–4.
dOne patient treated with TVR every 8 hours had no biopsy result available at baseline. This patient’s ﬁbrosis status was
therefore recorded as “other” and excluded from the efﬁcacy analyses.
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Rsimilar between the treatment groups. Of the 740 patients
treated, 28% had advanced ﬁbrosis (METAVIR F3–F4); 14%
had compensated cirrhosis, 57% had G1a, and 29% had
IL28B CC genotype. The majority of patients (92%) were
white, mean age was 48 years, and mean body mass index
was 27 kg/m2. At baseline, 85% of patients had an HCV RNA
level 800,000 IU/mL. Baseline TVR-resistant variants
were uncommon (2.4% T54S, 1.5% V36L, and <0.5% V36I/
M, I132V, or R155K).Efﬁcacy
SVR12 was 74.3% with TVR twice daily and 72.8% with
TVR every 8 hours (Figure 1A). The adjusted difference in
response between groups was 1.5% (95% CI, –4.9% to
12.0%), with the lower 95% CI (–4.9%) exceeding the non-
inferiority margin of –11%. Thus, noninferiority of TVR twice
daily compared with every 8 hours was established. Non-
inferiority was also conﬁrmed in the per-protocol population.
The treatment difference and 95% CI between TVR twice
daily and every 8 hours was 1.3% (–4.8% to 11.8%) based onSVR12 estimates of 76.3% and 75.1%, respectively. Results
obtained for the sensitivity analyses supported the ITT and
per-protocol efﬁcacy results. The secondary end point, SVR at
week 24, was achieved in 74.8% of patients treated with TVR
twice daily and 72.8% of patients treated with TVR every 8
hours (see Supplementary Results). Relapse rates were
similar between those treated with TVR twice daily (7.7%)
and every 8 hours (6.5%).
Virological response by IL28B genotype showed that the
efﬁcacy of TVR twice daily versus every 8 hours was similar
regardless of IL28B genotype (Figure 1B). SVR12 was higher
in patients with CC versus non-CC genotypes (90% vs 67%,
respectively; P < .0001). In a post hoc analysis, IL28B ge-
notype was strongly associated with SVR12 after adjust-
ment for other baseline factors, including ﬁbrosis stage
(odds ratio, 5.00; 95% CI, 3.01–8.30; P < .0001). Virological
response rates for TVR dosing twice daily and every 8 hours
were also generally comparable across ﬁbrosis stage sub-
groups (Figure 1C). In patients without cirrhosis, SVR12 rates
were78%(245/315) and77%(246/321) for TVR twice daily
and every 8 hours, respectively; in patients with cirrhosis,
Figure 1. SVR12 in pa-
tients treated with TVR
twice daily, TVR every 8
hours, and all patients (A)
overall, (B) by IL28B geno-
type, (C) HCV genotype,
and (D) by liver disease
stage.
Figure 2. SVR12 in patients treated with TVR twice daily and
TVR every 8 hours according to baseline subgroup.
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LIVERSVR12 rates were 54% (29/54) and 49% (24/49), respec-
tively. Overall, SVR12 was lower in patients with cirrhosis
versus those without (51% vs 77%, respectively; P¼ .0001).
When IL28B genotype and ﬁbrosis stage were considered
together, the highest SVR12 rate (90%; 95% CI, 84%–94%)
was observed in patients with CC genotype with F0 to F2
ﬁbrosis stage and the lowest SVR12 rate (47%; 95%CI, 39%–
55%) was observed in patients with non-CC genotype with
advanced ﬁbrosis or cirrhosis (F3–F4). Both IL28B genotype
andﬁbrosis stage correlated stronglywith SVR12 (P< .0001).
Subgroup analyses for baseline characteristics, including
sex, region, bodymass index, insulin resistance (as measured
by homeostasis model assessment of insulin resistance), HCV
RNA level, and HCV genotype (1a and 1b), showed similar
SVR12 outcomes for TVR twice daily and every 8 hours
(Figure 2). The low numbers of patients older than 65 years
and who were Asian, black, or “other” race meant no reliable
conclusions could be drawn on differences in SVR12 rate
between the 2 TVR dosing regimens in these subgroups.
The total treatment duration was determined by RVR
rates, which were similar with TVR twice daily (69.4%) and
every 8 hours (67.4%). For patients who achieved RVR and
were eligible for 24 weeks of treatment (68.4%), SVR rates
were 86.3% and 85.2% for TVR twice daily and every
8 hours, respectively. In patients with cirrhosis who ach-
ieved RVR, SVR rates after 24 weeks of treatment were
67.9% for TVR twice daily and 58.6% for TVR every 8 hours.
The SVR12 rate for the minority of patients who did notachieve RVR was 47% for both dosing regimens. Overall, the
extended RVR rates (<25 IU/mL, target not detectable at
weeks 4 and 12) were 66.1% and 63.1% for TVR twice daily
and every 8 hours, respectively. The proportion of patients
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for both groups.
On-treatment virological failure was observed in 38
(10.3%) and 36 (9.7%) patients treated with TVR twice
daily and every 8 hours, respectively. The proportion of
patients meeting a virological stopping rule was similar in
those treated with TVR twice daily (8.1%) and every 8
hours (9.2%). The proportion of patients with on-treatment
virological failure during treatment with TVR was 4.3% in
those treated twice daily and 6.2% in those treated every 8
hours. After treatment with TVR, the proportion of patients
with on-treatment virological failure was 6.0% in those
treated twice daily and 3.5% in those treated every 8 hours.
Overall, 54 of 369 patients (14.6%) treated with TVR
twice daily and 62 of 371 patients (16.7%) treated with TVR
every 8 hours had TVR-resistant variants at time of failure.
TVR-resistant variants were present in the majority of non-
SVR patients with available sequence data (70% in those
treated twice daily and 72% in those treated every 8 hours).
Variants V36M, R155K, and R155T (in G1a) and V36A,
T54A, and A156S (in G1b) were identiﬁed as signiﬁcantly
enriched in non-SVR patients in both treatment groups.
There was no notable difference in the type of variants
between the groups.
Adherence
E-diary and pill count adherence data were available for
700 patients (95%). Mean adherence rates to treatment
with TVR calculated using a pill count was high in patients
treated with TVR twice daily and every 8 hours (Table 2).
Mean adherence rates to treatment with TVR reported using
the e-diary were also high for TVR twice daily compared
with every 8 hours for both the imputed (where missing
e-diary entries were included and designated as 0%
adherent) and observed data sets. Two patients (0.5%) in
the group treated every 8 hours discontinued TVR because
of noncompliance. No patients in the group treated twice
daily discontinued TVR for this reason.
Safety
During the TVR treatment phase, those treated with TVR
twice daily had a similar safety proﬁle to that of those
treated every 8 hours (Table 3). This was also true for safety
assessments during the overall treatment phase (from the
date of ﬁrst intake of study drug to the last intake of study
drug plus 30 days) (see Supplementary Results). Fatigue,
pruritus, anemia, nausea, rash, and headache were the most
frequent AEs, occurring in >25.0% of patients in both
groups during the TVR (Table 3) and overall treatment
phases. Anemia, rash, pruritus, anorectal signs and symp-
toms, and injection site reaction SSC events were observed
in a similar proportion of patients treated with TVR twice
daily and every 8 hours. Serious AEs, mainly anemia, were
reported in 8% of patients treated with TVR twice daily
versus 9% of patients treated every 8 hours. AEs leading to
discontinuation of TVR occurred in 15% versus 19% of
patients treated with TVR twice daily and every 8 hours,
respectively (mainly due to rash, anemia, and pruritus).Serious AEs and discontinuations of TVR due to AEs
occurred in 14% and 21% of patients with cirrhosis treated
with TVR twice daily or every 8 hours, respectively, and 8%
and 16% of those without cirrhosis, respectively. One pa-
tient in the group treated every 8 hours died during treat-
ment; this patient had a brain neoplasm that was not
considered related to treatment.
Subgroup analyses, including liver ﬁbrosis stage, showed
no relevant differences within each SSC between those
treated with TVR twice daily and those treated every 8 hours
during the TVR treatment phase (data not shown) in serious
AEs and AEs leading to permanent discontinuation of TVR.
No differences were observed in the incidence of rash
SSC between the 2 treatment groups: 51% (twice daily)
versus 54% (every 8 hours). During the TVR treatment
phase, drug rash with eosinophilia and systemic symptoms
was reported in 1 patient treated with TVR twice daily. One
patient treated with TVR every 8 hours was reported to
have drug rash with eosinophilia and systemic symptoms
during the overall treatment phase.
The incidence of grade 3 AEs was 42% for TVR twice
daily and 38% for TVR every 8 hours (Table 3). AEs of at
least grade 3 severity that were most frequently considered
at least possibly related to TVR were anemia and rash SSC
events.
The total incidence of anemia SSC eventswas 45% for TVR
twice daily versus 44% for TVR every 8 hours. The incidence
of grade3 anemia SSCwas higher for TVR twice daily versus
every 8 hours (26% [95%CI, 21.4%–30.5%] vs 19% [15.0%–
23.2%]). The kinetics of anemia appeared similar between the
treatment groups. The incidence of SSC events reached its
highest value during weeks 5 to 8 in both treatment groups
and decreased thereafter. In those treated with TVR twice
daily and every 8 hours, respectively, the prevalence of ane-
mia SSC events in patients on treatment was 46.6% and
46.6% during weeks 0 to 16, 39.7% and 39.9% during weeks
17 to 32, and 25.4% and 24.6% during weeks 33 to 48. Sub-
group analyses by age, race, body mass index, ﬁbrosis stage,
and IL28B genotype showed that there were no relevant
differences between those treated with TVR twice daily and
those treated every 8 hours in the incidence of anemia SSC
events during the TVR treatment phase.
Although the incidence of grade 3 anemia was higher
in those treated with TVR twice daily compared with those
treated every 8 hours, changes in hemoglobin level from
baseline over time were similar between treatment groups
(4.7 g/dL for each arm). During the TVR treatment phase, a
decrease in hemoglobin level of grade 3 (<9.0 g/dL [<5.4
mmol/L] or any decrease 4.5 g/dL [2.7 mmol/L] from
baseline) was observed in a similar proportion of patients in
each treatment group: 59% of patients treated with TVR
twice daily and 55% of patients treated every 8 hours.
Grade 3/4 anemia SSC events occurred in 27% of patients
with cirrhosis and 21% of patients without cirrhosis. There
were no relevant differences in the incidence of grade 3 he-
moglobin abnormalities between patients with and without
cirrhosis. Treatment with TVR twice daily was associated with
a higher incidence of grade3 anemia over TVR every 8 hours
in patients with cirrhosis (35% vs 18%, respectively), but the
Table 2.Adherence to Treatment With TVR by Treatment Arm, Based on E-Diary and Pill Count Methods
Adherence method Statistic TVR twice daily (n ¼ 369)a TVR every 8 hours (n ¼ 371)a
Pill count (imputed) Mean (SE) 99 (0.2) 98 (0.3)
Median 100 100
Range 75–100 32–100
e-diary (imputed)b Mean (SE) 87 (1.1) 85 (1.2)
Median 95 94
Range 0–100 0–100
e-diary (observed data) Mean (SE) 95 (0.5) 92 (0.7)
Median 99 97
Range 0–100 0–100
aE-diary for patients treated with TVR every 8 hours, n ¼ 353; e-diary for patients treated with TVR twice daily, n ¼ 347.
bImputation method in which missing e-diary entries were included and designated as 0% adherent.
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LIVERmean change in hemoglobin level from baseline over timewas
similar between those treated with TVR twice daily and those
treated every 8 hours by ﬁbrosis stage.
In an exploratory, multivariable logistic regression
analysis (n ¼ 731), baseline factors signiﬁcantly associated
with the development of anemia (as reported by the
investigator) during treatment with TVR were low baseline
hemoglobin level, high dose of RBV, age, and cirrhosis (P <
.05). There was no effect of treatment arm on overall
occurrence of anemia (P ¼ .9194) and the effects ofTable 3.Summary of AEs During the TVR Treatment Phase
TVR twice daily (n ¼
Any AE 360 (98)
Serious AE 28 (8)
Deatha 0
Grade 3 AE 156 (42)
Grade 4 AE 23 (6)
Any AE leading to permanent
discontinuation of TVR
57 (15)
Any treatment-related AE considered
possibly related to TVRb
344 (93)
Most frequent AEsc
Fatigue 173 (47)
Pruritus 159 (43)
Anemia 157 (43)
Nausea 128 (35)
Rash 129 (35)
Headache 87 (24)
Anemia SSC events 167 (45)
Grade 3 anemia 95 (26)
Rash SSC events 189 (51)
Grade 3 rash 18 (5)
Pruritus SSC events 170 (46)
Electrocardiography/QT SSC events 12 (3)
Anorectal signs and symptoms SSC events 99 (27)
Injection site reaction SSC events 39 (11)
NOTE. All values are expressed as n (%).
SSC, grouped AE terms representing similar medical concepts
predeﬁned special search category was counted but counted o
aOne patient died during the study of a brain neoplasm that was
the investigator.
bConsidered at least possibly related to TVR by an investigator
cPreferred terms (in >25% of the patients in any treatment groprognostic factors were similar between the TVR groups,
with the exception that the effect of cirrhosis on anemia was
not observed with TVR twice daily. It should be noted that
the study was not designed or powered to identify factors
associated with the development of anemia per se.
The dose of RBV was reduced in 23% of patients treated
with TVR twice daily and in 25% of patients treated every 8
hours at a median of 9 weeks from initiation of TVR. Tem-
porary discontinuations of RBV due to anemia occurred in
14% of patients treated with TVR twice daily and in 9% of369) TVR every 8 hours (n ¼ 371) All patients (N ¼ 740)
367 (99) 727 (98)
35 (9) 63 (9)
1 (0.3) 1 (0.1)
139 (38) 295 (40)
24 (7) 47 (6)
69 (19) 126 (17)
335 (90) 679 (92)
177 (48) 350 (47)
157 (42) 316 (43)
151 (41) 308 (42)
142 (38) 270 (37)
132 (36) 261 (35)
107 (29) 194 (26)
162 (44) 329 (45)
70 (19) 165 (22)
199 (54) 388 (52)
22 (6) 40 (5)
171 (46) 341 (46)
11 (3) 23 (3)
116 (31) 215 (29)
46 (12) 85 (12)
used to ensure that each patient with an event included in a
nly once.
considered not related to TVR, PEG-IFN alfa-2a, and RBV by
.
up).
Table 4.Population PK Parameter Estimates of TVR at Steady State After Administration of TVR Twice Daily or TVR Every 8
Hours in Combination With PEG-IFN/RBV
PK parameter estimate, mean  SD
TVR bid
n ¼ 369 (n ¼ 203*)
TVR q8h
n ¼ 371 (n ¼ 199*)
AUCs,ss (h $ ng/mL), mean  SD 43,539  12,478 27,749  8640
AUC24,ss (h $ ng/mL), mean  SD 87,072  24,960 83,256  25,920
Cavg,ss (ng/mL), mean  SD 3628  1040 3469  1080
Ctrough,ss (ng/mL), mean  SD 2537  797 2987  987
Cmax,ss (ng/mL), mean  SD 4307  1233 3732  1133
Least-square mean ratioa (90% CI)
AUC24,ss (h $ ng/mL) 1.08 (1.02–1.13)
b
Ctrough,ss (ng/mL) 0.878 (0.827–0.930)
Cmax,ss (ng/mL) 1.18 (1.12–1.24)
NOTE. The PK analysis was performed in a subset of patients.
aTVR twice daily/PR (test) versus TVR every 8 hours/PEG-IFN and RBV (reference).
bEmpirical Bayesian estimates determined using a population PK modeling approach showed the ratio of telaprevir AUC24
between treatment arms falls within the limits of bioequivalence (0.80–1.25).
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Rpatients treated every 8 hours. Blood transfusions and/or
erythropoietin-stimulating agents were received by 17% of
those treated with TVR twice daily (blood transfusions,
8.4%; erythropoietin-stimulating agents, 10.6%) and 13.5%
of those treated every 8 hours (blood transfusions, 8.6%;
erythropoietin-stimulating agents, 7.8%) during the overall
treatment phase (P > .05). Anemia events leading to per-
manent discontinuation of TVR occurred in 5% of patients
treated with TVR twice daily and every 8 hours.
Increases in creatinine levels occurred in 6.8% of pa-
tients during the TVR treatment phase. All but one of these
abnormalities was grade 1 or 2 in severity. One patient
treated with TVR every 8 hours had a grade 3 increase in
creatinine level and renal failure (grade 3 AE). Hyperuri-
cemia was reported as a grade 3/4 AE for 5 patients treated
with TVR every 8 hours and for 7 patients treated with TVR
twice daily. Any other changes in creatinine levels were
small. In a post hoc exploratory analysis, 41 of 365 patients
(11.2%) treated with TVR twice daily and 40 of 368 patients
(10.9%) treated every 8 hours had a glomerular ﬁltration
rate of <60 mL/min/1.73 m2 during therapy.
Infections occurred in a similar proportion of patients in
each treatment arm: 68 (18.3%) and 64 (17.3%) patients
treated with TVR every 8 hours and twice daily, respec-
tively. No grade 3/4 infections were reported.
Electrocardiogram parameters were generally similar
between those treated with TVR twice daily and every 8
hours. None of the patients had a QTcF value >500 milli-
seconds or an increase from baseline >60 milliseconds.PK
A total of 402 patients provided sparse plasma samples:
203 treated with TVR twice daily and 199 treated with TVR
every 8 hours. Therefore, the PK data represent estimates
derived from approximately 55% of all study participants.
As expected,maximumsteady-state concentration (Cmax,ss)
was higher and predose steady-state concentration (Ctrough,ss)
was lower in those treated with TVR twice daily than in thosetreated with TVR every 8 hours (Table 4). Total exposure to
TVR (measured as area under the plasma concentration-time
curve from time of administration up to 24 hours [AUC24,ss])
was similar across treatment groups. The mean (SD) model-
predicted TVR AUC24,ss values were similar in patients
regardless of RVR but were slightly higher in patients who
achieved SVR12 (89,787 25,531 h $ ng/mL [twice daily] and
84,931  26,739 h $ ng/mL [every 8 hours]) compared with
thosepatientsnotachievingSVR12(79,00121,419h$ng/mL
[twice daily] and76,55921,375h $ng/mL [every 8 hours]).
For both population estimates, all mean parameters in those
treated with TVR twice daily were within 15% of those
treated every 8 hours. TVR exposures were analyzed by
subgroups, including IL28B genotype and cirrhosis status.
Similar mean exposures were noted for all IL28B genotypes.
The mean Cmax,ss (SD) was lower in patients with cirrhosis
compared with noncirrhotic patients (3569  1181 ng/mL
and 4100  1218 ng/mL, respectively). Mean AUC24,ss ex-
posures in patients with cirrhosis treated with TVR every 8
hourswere lower than those in patientswith cirrhosis treated
with TVR twice daily (64,493 17,407 ng $ h/mL and 84,404
23,559ng $h/mL, respectively) orpatientswithout cirrhosis
treated with either regimen (86,176  25,834 ng $ h/mL and
87,57725,075ng $h/mL, respectively).MeanCtrough,ss levels
were lower forpatientswith cirrhosis treatedwithTVRevery8
hours comparedwith thosewithout cirrhosis (2309 656 ng/
mL and 2476  818 ng/mL, respectively); no apparent dif-
ferencewas observed formeanCtrough,ss values in patientswith
orwithout cirrhosis treatedwith TVR twice daily (3094 990
ng/mL and 2549  794 ng/mL, respectively).
The mean exposure to TVR was similar in patients with
or without rash, irrespective of severity. No differences
were apparent in relative exposure between the 2 groups
with regard to hemoglobin toxicities.
Regardless of TVR regimen, observed mean PEG-IFN and
RBV concentrations at weeks 4 and 8were similar. Therewere
no apparent differences between the treatment groups in pre-
dictedTVRexposures forpatients experiencinganAE leading to
permanent discontinuation. Furthermore, there were no
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LIVERclinically relevant differences between treatment groups in the
pattern of individual worst QTcF interval values or changes
from baseline and Cmax,ss values of TVR (data not shown).Discussion
OPTIMIZE is the ﬁrst randomized, phase 3 clinical study
to investigate the use of TVR twice daily versus every 8
hours in combination with PEG-IFN/RBV in treatment-naive
patients with G1 chronic HCV infection. At baseline, the
majority of patients had a high viral load (800,000 IU/mL)
and almost one-third (28%) had ﬁbrosis stage F3 to F4,
including 14% with cirrhosis; 57% of patients had G1a
subtype, and 71% of patients had a non-CC IL28B genotype.
Therefore, data from OPTIMIZE may apply to a relatively
difﬁcult-to-treat population.
The results from this study show that TVR twice daily is
noninferior to dosing every 8 hourswith regard to SVR. These
ﬁndings are consistent with the phase 2 C208 study in which
SVR rates were similar between groups;>80% of patients in
the C208 study achieved SVR regardless of the dosing fre-
quency of TVR.3 However, the phase 2 study included only 4
cirrhotic patients, which may have contributed to the
observed difference in SVR rates between the 2 studies.
In OPTIMIZE, subgroup analyses for a spectrum of
baseline characteristics, including those typical of patients
more challenging to treat, showed strikingly similar SVR12
outcomes for treatment with TVR twice daily and every 8
hours. The number and type of TVR-resistant variants
detected in patients who did not achieve SVR12 were
similar for TVR twice daily and every 8 hours. Evaluation of
the data by IL28B genotype and liver ﬁbrosis stage showed
numerically higher response rates in patients with IL28B CC
genotype and F0 to F2 liver ﬁbrosis stage than patients with
non-CC genotypes with advanced ﬁbrosis (F3–F4).
There were no new clinically relevant ﬁndings with TVR
administered either twice daily or every 8 hours compared
with the known safety proﬁle.12–14 Anemia SSC was re-
ported more frequently in this open-label study than in
previous studies, possibly related to greater recognition of
TVR-related anemia. The overall incidence of grade 3
anemia was higher for TVR twice daily vs every 8 hours
(26% vs 19%). However, the mean change in hemoglobin
level and the incidence of treatment-emergent hemoglobin
abnormalities were similar in both groups.
Comparing the PK-pharmacodynamic relationships,
there were no relevant differences in virological responses
for those treated with TVR twice daily and every 8 hours.
Although some variability was seen between different
adherence measures, mean adherence was high by all
analysis methods for TVR twice daily and every 8 hours. In
OPTIMIZE, a multivariate analysis showed that higher
adherence was associated with a greater probability of
achieving SVR12, irrespective of adherence measure.15
Although the sample size of the overall study was well
powered to show noninferiority and to meet the study objec-
tives, it was not large enough to allow meaningful, multifactor
subgroup analyses on the combination of HCV genotype
(1a/1b), IL28B genotype, and liver ﬁbrosis stage. Thepopulation recruited was predominantly white, and the low
number of Asian and black patients means that no reliable
conclusions can be drawn from the analysis for these sub-
groups. A further limitation of the study is that PK blood
samples (sparse sampling) were obtained from only 55% of
participants.
In conclusion, both TVR 1125 mg twice daily and 750 mg
every 8 hours were shown to have high rates of SVR12, a
low incidence of virological failure, and a comparable safety
and tolerability proﬁle when administered in combination
with PEG-IFN/RBV. The ﬁndings of this study support the
use of TVR twice daily regardless of ﬁbrosis stage or IL28B
genotype, thus offering the potential of simpliﬁed TVR
dosing to G1 HCV-infected patients, including those with
advanced ﬁbrosis or cirrhosis.
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Supplementary Results
A summary of AEs for the TVR treatment phases is
provided in Table 3. Supplementary Table 2 summarizes the
AEs for the overall treatment phase.
RVR (week 4) and eRVR (week 12) data presented in the
report were analyzed as “HCV RNA <25 IU/mL, target not
detected,” because this assay cutoff (lower limit of detec-
tion) was used to determine treatment duration in this
study, in accordance with the approved European and US
labeling.
Data on the number of patients at weeks 4 and 12 with
virological response using HCV RNA <25 IU/mL, target not
detected, or alternatively using HCV RNA <25 IU/mL are
shown in Supplementary Table 3.
Supplementary Methods
The primary end point of this study was the proportion
of patients in each treatment group who achieved
SVR12planned, deﬁned as having plasma HCV RNA levels <25
IU/mL using the last available HCV RNA assessment 12
weeks after the last planned dose of HCV study drug. In this
analysis, the virological outcome was based only on the HCV
RNA assessment in the week 12 follow-up visit window
(snapshot approach).
Sensitivity analyses were used to compare virological
response rates of treatment with TVR every 8 hours and
TVR twice daily. The sensitivity analyses used slightly
different “deﬁnitions” of SVR12 relating to the assay cutoff
and data point(s) used. SVR12planned (snapshot, target not
detected) used the lower limit of detection of the HCV RNA
assay rather than the lower limit of quantiﬁcation (25 IU/
mL). SVR12planned (classic, target not detected) also used the
lower limit of the detection of the HCV RNA assay, but this
threshold had to be met at the end of treatment and up to 12
weeks after the last planned dose of HCV study drug. These
data are summarized in Supplementary Table 1.
Supplementary
Figure 1. Patient
disposition.
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Supplementary Table 1.Comparison of Virological Response After Administration of TVR Twice Daily or TVR Every 8 Hours in
Combination With PEG-IFN/RBV
Sensitivity analysis TVR every 8 hours (n ¼ 371) TVR twice daily (n ¼ 369) All patients (N ¼ 740)
SVR12planned
(snapshot, target not detected)
SVR12, n (%) 269 (72.5) 274 (74.3) 543 (73.4)
Differencea (%) (95% CIb) 1.7 (4.8 to 12.1)
SVR12planned
(classic, target not detected)
SVR12, n (%) 271 (73.0) 268 (72.6) 539 (72.8)
Differencea (%) (95% CIb) 0.4 (8.5 to 8.4)
aObserved difference.
bFrom logistic regression model.
Supplementary Table 2.Summary of AEs During the Overall Treatment Phase
TVR twice daily (n ¼ 369) TVR every 8 hours (n ¼ 371) All patients (N ¼ 740)
Any AE 361 (98) 368 (99) 729 (99)
Serious AE 42 (11) 48 (13) 90 (12)
Deatha 0 1 (0.3%) 1 (0.1%)
Grade 3 AE 180 (49) 160 (43) 340 (46)
Grade 4 AE 36 (10) 35 (9) 71 (10)
Any AE leading to permanent
discontinuation of TVR
57 (15) 70 (19) 127 (17)
Any treatment-related AE considered
possibly related to TVRb
347 (94) 359 (97) 706 (96)
Most frequent AEsc
Fatigue 185 (50.1) 181 (48.8) 366 (49.5)
Pruritus 172 (46.6) 170 (45.8) 342 (46.2)
Anemia 174 (47.2) 166 (44.7) 340 (45.9)
Nausea 136 (36.9) 145 (39.1) 281 (38.0)
Rash 139 (37.7) 139 (37.5) 278 (37.6)
Headache 93 (25.2) 122 (32.9) 215 (29.1)
Anemia SSC events 184 (49.9) 178 (48.0) 362 (48.9)
Rash SSC events 201 (54.5) 210 (56.6) 411 (55.5)
Pruritus SSC events 183 (49.6) 185 (49.9) 368 (49.7)
Electrocardiogram/QT SSC events 14 (3.8) 14 (3.8) 28 (3.8)
Anorectal signs and symptoms SSC events 106 (28.7) 119 (32.1) 225 (30.4)
Injection site reaction SSC events 42 (11.4) 47 (12.7) 89 (12.0)
NOTE. All values are expressed as n (%).
SSC, grouped AE terms representing similar medical concepts used to ensure that each patient with an event included within a
predeﬁned special search category was counted but counted only once.
aOne patient died during the study of a brain neoplasm that was considered not related to TVR, PEG-IFN alfa-2a, and RBV by
the investigator.
bConsidered at least possibly related to TVR by an investigator.
cPreferred terms (in >25% of the patients in any treatment group).
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Supplementary Table 3.Virological Response at Weeks 4 and 12 During Administration of TVR Twice Daily or TVR Every 8 Hours in Combination With PEG-IFN/RBV
Parameter Time point Value
TVR every 8 hours (n ¼ 371) TVR twice daily (n ¼ 369)
n % CI n % CI
Virological response (<25 IU/mL target not detected)
NC ¼ F (non-VF)
Nonresponder 109 29.4 (24.8–34.3) 101 27.4 (22.9–32.2)
Week 4 Responder (RVR) 250 67.4 (62.4–72.1) 256 69.4 (64.4–74.0)
Missing: dropout unrelated to VF 12 3.2 (1.7–5.6) 12 3.3 (1.7–5.6)
Nonresponder 30 8.1 (5.5–11.3) 28 7.6 (5.1–10.8)
Week 12 Responder (complete early virological response) 306 82.5 (78.2–86.2) 313 84.8 (80.7–88.3)
Missing: dropout unrelated to VF 35 9.4 (6.7–12.9) 28 7.6 (5.1–10.8)
Virological response (<25 IU/mL) NC ¼ F (non-VF) Nonresponder 31 8.4 (5.7–11.7) 27 7.3 (4.9–10.5)
Week 4 Responder (RVR) 328 88.4 (84.7–91.5) 330 89.4 (85.8–92.4)
Missing: dropout unrelated to VF 12 3.2 (1.7–5.6) 12 3.3 (1.7–5.6)
Nonresponder 24 6.5 (4.2–9.5) 18 4.9 (2.9–7.6)
Week 12 Responder (complete early virological response) 312 84.1 (80.0–87.7) 323 87.5 (83.7–90.7)
Missing: dropout unrelated to VF 35 9.4 (6.7–12.9) 28 7.6 (5.1–10.8)
NC ¼ F, noncompleter equals failure; non-VF, nonvirological failure; VF, virological failure; HCV RNA <25 IU/mL, target not detected at week 4 of treatment; HCV RNA <25
IU/mL, target not detected at week 12 of treatment.
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